ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen P. Carey Sells 7,500 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now owns 154,468 shares of the company’s stock, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $53.88 on Thursday. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -97.96 and a beta of 0.73. The stock’s 50-day moving average is $58.00 and its 200 day moving average is $60.17. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 1-year low of $52.00 and a 1-year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. During the same period last year, the firm posted $1.05 earnings per share. The business’s revenue was up 12.5% compared to the same quarter last year. On average, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ANIP has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target for the company. Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective on the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Finally, Raymond James boosted their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $77.71.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Texas Permanent School Fund Corp grew its stake in shares of ANI Pharmaceuticals by 1.3% during the second quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock valued at $852,000 after buying an additional 178 shares during the last quarter. Louisiana State Employees Retirement System grew its position in ANI Pharmaceuticals by 2.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after acquiring an additional 200 shares during the last quarter. Arizona State Retirement System increased its stake in ANI Pharmaceuticals by 4.7% in the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after purchasing an additional 211 shares during the period. Thrivent Financial for Lutherans lifted its position in ANI Pharmaceuticals by 2.3% in the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after purchasing an additional 299 shares during the last quarter. Finally, New York State Teachers Retirement System lifted its position in ANI Pharmaceuticals by 1.7% in the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after purchasing an additional 394 shares during the last quarter. 76.05% of the stock is owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.